A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

UMB Bank NA filed suit against Bristol-Myers in 2021, alleging that the company intentionally slow-rolled the approval ...

Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of ...

Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients ...